Literature DB >> 18725873

Sleeping beauty vector system moves toward human trials in the United States.

David A Williams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725873     DOI: 10.1038/mt.2008.169

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  30 in total

1.  Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains.

Authors:  Katrin Voigt; Andreas Gogol-Döring; Csaba Miskey; Wei Chen; Toni Cathomen; Zsuzsanna Izsvák; Zoltán Ivics
Journal:  Mol Ther       Date:  2012-07-10       Impact factor: 11.454

2.  Herpes simplex virus/Sleeping Beauty vector-based embryonic gene transfer using the HSB5 mutant: loss of apparent transposition hyperactivity in vivo.

Authors:  Suresh de Silva; Michael A Mastrangelo; Louis T Lotta; Clark A Burris; Zsuzsanna Izsvák; Zoltán Ivics; William J Bowers
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

3.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Authors:  Hiroki Torikai; Andreas Reik; Pei-Qi Liu; Yuanyue Zhou; Ling Zhang; Sourindra Maiti; Helen Huls; Jeffrey C Miller; Partow Kebriaei; Brian Rabinovich; Brian Rabinovitch; Dean A Lee; Richard E Champlin; Chiara Bonini; Luigi Naldini; Edward J Rebar; Philip D Gregory; Michael C Holmes; Laurence J N Cooper
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 4.  Transposon tools: worldwide landscape of intellectual property and technological developments.

Authors:  Fabien Palazzoli; François-Xavier Testu; Franck Merly; Yves Bigot
Journal:  Genetica       Date:  2009-12-03       Impact factor: 1.082

Review 5.  Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

Authors:  Perry B Hackett; Elena L Aronovich; David Hunter; Myra Urness; Jason B Bell; Steven J Kass; Laurence J N Cooper; Scott McIvor
Journal:  Curr Gene Ther       Date:  2011-10       Impact factor: 4.391

6.  Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery.

Authors:  Jason B Bell; Elena L Aronovich; Jeffrey M Schreifels; Thomas C Beadnell; Perry B Hackett
Journal:  Mol Ther       Date:  2010-07-13       Impact factor: 11.454

Review 7.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

8.  Excision efficiency is not strongly coupled to transgenic rate: cell type-dependent transposition efficiency of sleeping beauty and piggyBac DNA transposons.

Authors:  Orsolya Kolacsek; Zsuzsa Erdei; Agota Apáti; Sára Sándor; Zsuzsanna Izsvák; Zoltán Ivics; Balázs Sarkadi; Tamás I Orbán
Journal:  Hum Gene Ther Methods       Date:  2014-08       Impact factor: 2.396

9.  piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Authors:  Pallavi V Raja Manuri; Matthew H Wilson; Sourindra N Maiti; Tiejuan Mi; Harjeet Singh; Simon Olivares; Margaret J Dawson; Helen Huls; Dean A Lee; Pulivarthi H Rao; Joseph M Kaminski; Yozo Nakazawa; Stephen Gottschalk; Partow Kebriaei; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

10.  Sleeping beauty system to redirect T-cell specificity for human applications.

Authors:  Sourindra N Maiti; Helen Huls; Harjeet Singh; Margaret Dawson; Matthew Figliola; Simon Olivares; Pullavathi Rao; Yi Jue Zhao; Asha Multani; Ge Yang; Ling Zhang; Denise Crossland; Sonny Ang; Hiroki Torikai; Brian Rabinovich; Dean A Lee; Partow Kebriaei; Perry Hackett; Richard E Champlin; Laurence J N Cooper
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.